Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients Treated With Teriflunomide and Alemtuzumab

Last updated: October 6, 2021
Sponsor: Sheba Medical Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Multiple Sclerosis

Covid-19

Neurologic Disorders

Treatment

N/A

Clinical Study ID

NCT05075499
8182-21 SMC
  • Ages > 18
  • All Genders

Study Summary

Phase IV, 3-armed, prospective, open-label, single-center, Israeli study, examining the response to SARS-CoV-2 vaccination in 30 teriflunomide-, 10 alemtuzumab-treated patients, and 30 age-matched (for the teriflunomide group) untreated MS patients. Treatments will be administered according to common local practice. Demographic, clinical, treatment-related and COVID-19-related data will be collected. Blood samples will be drawn for each participant at baseline (before COVID-19 vaccination), and at 1, 3, 6, (and possibly 12) months post 2nd dose of COVID-19 vaccine. Humoral, B-cell and T-cell responses will be evaluated.

Eligibility Criteria

Inclusion

Inclusion Criteria:

(1) Diagnosis of multiple sclerosis (MS) according to 2017 McDonald criteria. (2) Age >=18years.

(3) Treatment with Teriflunomide for at least 6 months/or 4 to 18 months after the lastcourse treatment with Alemtuzumab/or untreated.

(4) Signed written informed consent.

Exclusion

Exclusion Criteria:

(1) Cognitive decline that precludes understanding the study procedures.

Study Design

Total Participants: 70
Study Start date:
March 20, 2021
Estimated Completion Date:
September 30, 2022

Connect with a study center

  • Sheba Medical Center

    Ramat Gan, 52621
    Israel

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.